Factbites
 Where results make sense
About us   |   Why use us?   |   Reviews   |   PR   |   Contact us  

Topic: Corixa


Related Topics

In the News (Tue 21 May 19)

  
  NetSci: The Biotech YellowPages - Corixa Corporation   (Site not responding. Last check: 2007-10-13)
Corixa focuses exclusively on research and development, utilizing broad technology platforms whose components are combined in specific, potent T cell vaccines for the prevention and treatment of cancers and infectious diseases.
Corixa offers proprietary advances in three areas of vaccine technology; (1) antigens that trigger an immune response; (2) molecular mechanisms of vaccine delivery, ensuring this response is generated; and (3) adjuvants that encourage and strengthen this response.
Corixa follows a "partner early and often" credo, minimizing cash burn, sharing risk and accelerating this development of new vaccines and diagnostics for cancer and infectious diseases.
www.netsci.org /Resources/Biotech/Yellowpages/C/corixa.html   (383 words)

  
 Company Information   (Site not responding. Last check: 2007-10-13)
Corixa is engaged in discovery and development of innovative immunotherapeutic products to address debilitating and life-threatening conditions caused by cancer, infectious disease and autoimmune disease.
Corixa is co-developing BEXXAR therapy with GlaxoSmithKline (GSK) in the U.S. and with Amersham in Europe.
Corixa specializes in the development of cancer and infectious disease vaccines based on the activation of specialized T cells that recognize and kill pathogen-infected tissue or tumor cells.
www.hirehealth.com /ci/servlet/com.ci.jobseeker.CompanyDetails?ID=105765   (943 words)

  
 Corixa Corporation - news: Corixa and Genesis Research provide update on PVAC Treatment program   (Site not responding. Last check: 2007-10-13)
Corixa is a developer of immunotherapeutics with a commitment to treating and preventing cancer and infectious diseases by understanding and directing the immune system.
Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary product components on a standalone basis.
Corixa was founded in 1994 and is headquartered in Seattle, with additional operations in Hamilton, Mont., and South San Francisco.
www.corixa.com /?pid=release_detail&year=2003&ID=222   (829 words)

  
 HUM-MOLGEN: registry of biomedical companies - Corixa Corporation   (Site not responding. Last check: 2007-10-13)
Corixa's technologies aim to bring T cell attention to invading cancer cells or infectious agents without directing the immune response toward normal tissue.
Corixa is a leader in vaccine discovery and development, attracting partners for all its products at an early stage of development.
Corixa specializes in the discovery and development of disease-specific T cell vaccines based on proprietary antigens, antigen delivery and adjuvant technologies.
hum-molgen.org /companies/profile.php3/288   (434 words)

  
 Biotechnology News and Information Portal, biotech jobs and career resources Resources.
Corixa scientists hope to develop a\r\nnew type of vaccine that provides continuous protection within 1224\r\nhours after the first intranasal dose is delivered other vaccines can\r\ntake weeks to months to generate protection.
Corixa has conducted\r\nproof of principle studies in mice, showing rapid vaccineinduced\r\nprotection against otherwise lethal levels of influenza virus\r\nchallenge.\r\nWe are gratified that the NIH Biodefense Partnership program has\r\nshown interest in our TLR4targeted compounds, said David H. Persing,\r\nM.D., Ph.D, vice president of Discovery Research at Corixa and\r\nprincipal investigator on the contract.
Corixa scientists hope to develop a new type of vaccine that provides continuous protection within 12-24 hours after the first intranasal dose is delivered (other vaccines can take weeks to months to generate protection).
www.bioexchange.com /news/news_page.cfm?id=19281   (1108 words)

  
 Corixa hits new roadblock   (Site not responding. Last check: 2007-10-13)
Corixa Chairman and Chief Executive Steven Gillis, who was unavailable for comment yesterday, said in a statement that he was "extremely disappointed" by the delay.
Analysts also said jobs cuts at Corixa are likely, as it tries to lower its burn rate to compensate for missed revenues.
Corixa said yesterday that it has not made decisions about staff reductions yet.
seattlepi.nwsource.com /business/62215_corixa14.shtml   (780 words)

  
 Business Wire: Corixa Announces Initiation of Phase I Clinical... @ HighBeam Research   (Site not responding. Last check: 2007-10-13)
Corixa is exploring the use of these compounds as stand alone immunotherapies based on their ability to influence innate immune responses.
Corixa is exploring the use of these synthetic compounds as stand alone immunotherapies based on their recognition by TLR4s, and their possible lack of toxicity associated with natural TLR4 immunostimulants such as lipopolysaccharide.
Corixa's preclinical studies indicate that its TLR4 agonist candidate is absorbed into the body and is biologically active at mucosal, or mucous membrane, surfaces.
www.highbeam.com /library/doc0.asp?DOCID=1G1:115828352&refid=holomed_1   (1652 words)

  
 Business Wire: Corixa Reports Second Quarter Results
Corixa expects its quarterly revenues to continue to vary as it enters into new agreements, reaches certain research and development milestones and receives license and research and development payments under existing and new agreements.
Corixa announced on June 6, 2002, that it has initiated an additional U.S. clinical study designed to evaluate the potential effectiveness of PVAC treatment for patients with mild to moderate plaque psoriasis.
Corixa is a developer of immunotherapeutics with a commitment to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system.
www.findarticles.com /p/articles/mi_m0EIN/is_2002_August_8/ai_90224127   (1133 words)

  
 Ravalli Republic Online   (Site not responding. Last check: 2007-10-13)
Corixa, a biotech company with operations in Seattle, Hamilton and San Francisco, received approval of another cancer drug in June.
A new Corixa treatment for non-Hodgkins lymphoma approved for sale in the U.S. this summer was recently shown to have a high success rate when used as a two-part treatment with chemotherapy.
Corixa's Bexxar was chosen as the radio immunotherapy for the phase II study by the Southwest Oncology Group, a cooperative group funded by the National Cancer Institute.
www.ravallinews.com /articles/2003/09/23/news/news04.txt   (520 words)

  
 Ravalli Republic Online   (Site not responding. Last check: 2007-10-13)
Corixa, a Seattle-based biotech company, employs more than 100 people at its research and manufacturing facility on Old Corvallis Road in Hamilton and had plans to increase its personnel here to 258 in the coming years in conjunction with a $40 million expansion.
Corixa CEO Steven Gillis said in a press release this round of cuts will allow the company to pursue the commercialization of adjuvant products, compounds which when combined with a vaccine boost the body's immune response to the antigens.
Corixa purchased Ribi Immunochem, Inc., a Hamilton biotechnical company founded by scientist Edgar Ribi, in 1999 and focused on the research and manufacture of treatments in the fields of autoimmune diseases, cancer and infectious diseases.
www.ravallinews.com /articles/2004/12/16/news/news01.txt   (513 words)

  
 Bioterrorism has formidable foe in Corixa   (Site not responding. Last check: 2007-10-13)
Corixa hopes, in part, to create a product that could be used to protect people against anthrax, a potential biological warfare agent that is widely feared.
Corixa is working with a family of small molecules, called aminoalkyl glucosamine phosphates, or AGPs, to create compounds to ward off infections.
Corixa announced earlier this month that it has provided the FDA with all of the additional data that the agency requested.
seattlepi.nwsource.com /business/40841_corixa29.shtml   (1370 words)

  
 Corixa - Wikipedia, the free encyclopedia
Corixa is a biotechnology/pharmaceutical company based in Seattle, Washington involved in the development of immunotherapeutics to combat autoimmune diseases, infectious diseases, and cancer.
On 12th July 2005, the European pharmaceuticals giant GlaxoSmithKline completed the acquisition of Corixa.
GSK had formerly made use of the Corixa's MPL adjuvant in some of their vaccines.
en.wikipedia.org /wiki/Corixa   (134 words)

  
 HHP Discussion Forums - GSK acquires Corixa   (Site not responding. Last check: 2007-10-13)
GSK owns approximately 8% of the outstanding Corixa shares and additional holders of approximately 11% of the shares have agreed to vote their shares in favor of the transaction.
MPL®, a vaccine adjuvant from Corixa, is a key component in many of the novel and GSK Bio proprietary adjuvant systems used in the future vaccine pipeline of GSK Biologicals.
MPL (by Corixa) is the adjuvant used in Herpevac and the GSK hpv preventative vaccine.
www.racoon.com /dcforum/news/845.html   (1214 words)

  
 The Seattle Times: Business & Technology: Sales of Corixa cancer drug Bexxar lagging
But even if Corixa reaches its first-year goal — which would require sales in the second half to jump nearly fivefold — it is still a long way from reaching its dreams.
Despite the slow sales, Corixa said the success of some programs means it does not expect to lose more than the $60 million to $80 million it has forecast for this year.
Corixa also got about $12 million from the National Institutes of Health for immunology research, and the company has started human testing of a tuberculosis vaccine and an allergy treatment.
seattletimes.nwsource.com /html/businesstechnology/2001996146_corixanew04.html   (646 words)

  
 Corixa cuts jobs in South S.F., sells off products
Corixa, which is struggling to win government approval for a new medicine, absorbed what used to be South San Francisco's Coulter Pharmaceutical in an October 2000 stock swap valued at $758 million.
Corixa is appealing that FDA decision and hopes to persuade the government to reverse itself and review its current trial data.
Corixa's shares have suffered, plunging from the $40 range near the 2000 merger to close at $7.05 Thursday on a gain of 39 cents.
www.sfgate.com /cgi-bin/article.cgi?f=/c/a/2002/05/24/BU53022.DTL   (435 words)

  
 BioWorld Today
A major benefit to Corixa is the cost-savings, but the company also will continue to receive development and sales milestones, as well as royalties based on Bexxar sales in the U.S., Canada and Australasia.
Beginning this quarter and continuing through the middle of next year, Corixa expects to incur non-cash charges of up to $4.5 million and cash charges of up to $5.5 million for the transfer of Bexxar to GSK and the work force reduction.
Corixa reported in November that Bexxar sales were $2.5 million in the third quarter, compared with $2.2 million in the second quarter.
www.bioworld.com /servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=34276   (953 words)

  
 Breaking News: Corixa Announces Agreement to Be Acquired by GlaxoSmithKline; Shareholders to Receive $4.40 Per Share in ...   (Site not responding. Last check: 2007-10-13)
Selected Corixa Board Members and their investment funds, all of which collectively own approximately 11 percent of the outstanding voting shares of Corixa, have entered into support agreements pledging that they will vote all their shares in favor of the transaction at the meeting of Corixa stockholders.
Corixa's directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Corixa in connection with the transaction.
A description of certain of the interests of directors and executive officers of Corixa is set forth in the proxy statement for Corixa's 2005 annual meeting of stockholders, which was filed with the SEC on April 20, 2005.
www.genengnews.com /news/bnitem.aspx?name=516739XSL_NEWSML_TO_NEWSML_WEB.xml   (860 words)

  
 GSK acquires Corixa for €233m   (Site not responding. Last check: 2007-10-13)
In purchasing Corixa, GSK will no longer incur royalties and other costs under the existing agreements in place between GSK and Corixa nor will GSK incur royalties on future sales of their vaccines containing MPL.
MPL, a vaccine adjuvant from Corixa, is a key component in many of the adjuvant systems used in the future vaccine pipeline of GSK Biologicals.
GSK currently own approximately 8 per cent of the outstanding Corixa shares and additional holders of approximately 11 per cent of the shares have agreed to vote their shares in favour of the transaction.
www.drugresearcher.com /news/news-ng.asp?id=59747-gsk-acquires-corixa   (697 words)

  
 Abbott Laboratories and Corixa Enter Into Agreement for Chagas' Disease Blood Screening Technology
In a separate agreement, Corixa granted Abbott non-exclusive rights to develop non-nucleic acid-based diagnostic assays intended to detect mammaglobin, a marker that appears to be significantly over-expressed in breast cancer.
About Corixa Corixa is a developer of immunotherapeutics with a commitment to treating and preventing cancer and infectious diseases by understanding and directing the immune system.
Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary product components on a stand-alone basis.
www.prnewswire.com /cgi-bin/stories.pl?ACCT=104&STORY=/www/story/03-02-2004/0002120764&EDATE=   (1039 words)

  
 Boston.com / Business / GlaxoSmithKline to buy Corixa for $300M   (Site not responding. Last check: 2007-10-13)
Corixa Corp., a maker of vaccine additives that boost the immune system, on Friday said it agreed to be purchased by British pharmaceutical giant GlaxoSmithKline PLC in a $300 million cash deal.
GlaxoSmithKline owns about 8 percent of Corixa shares, and additional holders of about 11 percent of the shares have pledged their support for the transaction.
Corixa shares were halted for trading, having closed up 11 cents, or 3.7 percent, to $3.09 on the Nasdaq.
www.boston.com /business/articles/2005/04/29/glaxosmithkline_to_buy_corixa_for_300m?mode=PF   (466 words)

  
 Pharmalicensing.com: company news: Medicis and Corixa sign psoriasis agreement
Corixa will be responsible for development and manufacturing, and Medicis will be responsible for commercialization and distribution.
Corixa has an existing partnership in Japan for PVAC, with Zenyaku Kogyo Pharmaceuticals, and is seeking to add marketing partners for Europe and the rest of the world.
Corixa is a research- and development-based biotechnology company committed to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system.
www.pharmalicensing.com /news/adisp/966584106_399ce72a96281   (480 words)

  
 Corixa's Cancer Drug Hits FDA Wall
Corixa had also requested an accelerated, six-month review of Bexxar, but in its letter, the FDA told the company that the drug did not address an unmet medical need -- a key factor in granting so-called fast-track approval.
Bexxar is the most advanced and important drug in Corixa's pipeline, so a lengthy delay in its approval is an especially hard blow to the company's fortunes.
Wednesday, Corixa executives expressed extreme disappointment with the FDA decision and said they would request a meeting with the agency to discuss their options.
www.thestreet.com /pf/tech/adamfeuerstein/10012830.html   (359 words)

  
 CORIXA CORPORATION COMPLETES ACQUISITION OF RIBI IMMUNOCHEM RESEARCH, INC.   (Site not responding. Last check: 2007-10-13)
Corixa purchased Ribi for approximately $58.5 million, which consists of Corixa common stock and options valued at $48 million, cash of $7.9 million paid by Corixa to Ribi for the redemption of Ribi Series A preferred stock and transaction costs of approximately $2.6 million.
Corixa is a research- and development-based biotechnology company committed to treating and preventing diseases by understanding and directing the immune system.
Corixa was founded in 1994 and is headquartered in Seattle, Washington.
www.shareholder.com /corixa/news/19991007-11264.htm   (475 words)

  
 FDA rejects Corixa drug - Mar. 13, 2002
Corixa (CRXA: down $3.48 to $6.15, Research, Estimates) said it received a letter from the FDA that said data for Bexxar, a low-grade non-Hodgkin's lymphoma treatment, did not "provide sufficient evidence of the safety and net clinical benefit" of the drug and that new clinical trials would be needed.
According to Corixa, the FDA also decided there was not enough evidence to prove Bexxar addresses an unmet medical need, eliminating the possibility of fast-track approval.
The drug was on track for approval by early to mid-2001 when Corixa agreed to buy Coulter, including the rights to Bexxar.
money.cnn.com /2002/03/13/news/companies/corixa   (415 words)

  
 GlaxoSmithKline - Press Archive - Corixa and GlaxoSmithKline report on FDA review of Bexxar® therapy application
Corixa and GlaxoSmithKline are seeking approval of Bexxar therapy for the treatment of patients with B-cell, follicular, non-Hodgkin's lymphoma (NHL), with and without transformation, whose disease has relapsed following or is refractory to chemotherapy and is refractory to rituximab.
Corixa and GSK will discuss the FDA's PDUFA response in a conference call and webcast on Monday, May 5, 2003 at 8:00 a.m.
Corixa currently has multiple programs in clinical development, including several product candidates that have advanced to and through late stage clinical trials.
www.gsk.com /press_archive/press2003/press_05052003.htm   (1148 words)

  
 GlaxoSmithKline to Buy Corixa for $300 Million   (Site not responding. Last check: 2007-10-13)
In return, GSK will receive all scientific and business programs, activities, assets and related rights of Corixa, including the firm's manufacturing facility in Hamilton, Mont. The plant produces Monophosphoryl Lipid A (MPL), a novel adjuvant contained in many of the vaccines in GSK's pipeline.
In the past, GSK paid Corixa royalties for MPL, but those payments will come to an end once the acquisition is completed, GSK said.
Corixa's portfolio also includes other compounds, such as TLR4 agonists and antagonists, GSK said.
www.fdanews.com /dailies/drugdaily/2_94/news/40868-1.html   (202 words)

Try your search on: Qwika (all wikis)

Factbites
  About us   |   Why use us?   |   Reviews   |   Press   |   Contact us  
Copyright © 2005-2007 www.factbites.com Usage implies agreement with terms.